Alnylam's 'Day After' Revusiran Failure Bad, Maybe Not Catastrophic
Despite its stock price falling 48% 24 hours after the shuttering of lead candidate revusiran, Alnylam is encouraged by analyst reports indicating the failure does not read through to its overall pipeline. The biotech reaffirmed its timeline for its second Phase III candidate patisiran.
You may also be interested in...
Stockwatch: Is Alnylam’s Rare Disease Business Model Sustainable?
Alnylam’s fourth-quarter and full-year 2019 earnings announcement was only one of eight announcements made by the company since early February. With the fundamental basis of its orphan drug business model still unvalidated by a profit, perhaps the more recent announcements are meant to distract investors’ attention with different metrics.
Alnylam Set For Transformation As Patisiran Nears Market With Data Upgrade
Alnylam has outlined further data and analyses from the Phase III APOLLO study supporting the use of its selective interfering RNA agent, patisiran, as it nears the market for the treatment of hATTR amyloidosis.
Pfizer May Enjoy Blockbuster Cardiomyopathy Success With Tafamidis
Although tafamidis has been stalled at FDA for transthyretin-mediated polyneuropathy, Pfizer may have found a different path toward US approval with cardiovascular outcomes data in cardiomyopathy.